Seung Suh Hong
Direttore/Membro del Consiglio presso OCULAR THERAPEUTIX, INC.
Patrimonio netto: 37 519 $ in data 30/04/2024
Posizioni attive di Seung Suh Hong
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| OCULAR THERAPEUTIX, INC. | Direttore/Membro del Consiglio | 11/06/2019 | - |
| Independent Dir/Board Member | 11/06/2019 | - | |
Cellemedy Co., Ltd.
 Cellemedy Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Cellemedy Co., Ltd. develops next-generation cancer treatments to improve the health of people suffering from cancer. The company is based in Seongnam-si, South Korea. The South Korean company was founded in 2016. The CEO is Ha-Chul Kim. | Direttore operativo | 01/01/2021 | - |
| Presidente | 01/01/2021 | - | |
Novalgen Ltd.
 Novalgen Ltd. BiotechnologyHealth Technology Part of Convergys Capital Ltd., Novalgen Ltd. is a clinical stage immunology company based in Northwood Hills, UK. Novalgen is developing breakthrough immunotherapies for people with immunologically driven diseases using their autoregulation platform. The British company's lead program, NVG-111, is an ROR1-targeting bispecific antibody T-cell engager for the treatment of both hematological malignancies and solid tumors using their breakthrough bispecific antibody technology. The company's lead AR program, NVG-222, builds on the success of NVG-111 and is primed for entry into the clinic in 2024. The company was founded by Amit Chunilal Nathwani and has been the CEO since incorporation. | Direttore/Membro del Consiglio | 01/01/2021 | - |
| Novelgen Co. Ltd(South Korea) | Direttore/Membro del Consiglio | 01/04/2020 | - |
Storia della carriera di Seung Suh Hong
Precedenti posizioni note di Seung Suh Hong
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| Celltrion Healthcare Japan KK | Presidente | 01/01/2016 | 02/01/2019 |
| CELLTRION HEALTHCARE CO., LTD. | Amministratore Delegato | 01/11/2014 | 01/12/2015 |
| Corporate Officer/Principal | 01/04/2002 | 01/11/2014 | |
| Presidente | 01/11/2014 | 01/12/2015 |
Formazione di Seung Suh Hong
| Seoul National University | Doctorate Degree |
Statistiche
Distribuzione geografica
| Corea del Sud | 5 |
| Stati Uniti | 2 |
| Giappone | 2 |
Posizioni
| Director/Board Member | 3 |
| President | 3 |
| Independent Dir/Board Member | 1 |
Settori
| Health Technology | 4 |
| Consumer Services | 2 |
| Commercial Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| OCULAR THERAPEUTIX, INC. | Health Technology |
| CELLTRION HEALTHCARE CO., LTD. | Health Technology |
| Aziende private | 4 |
|---|---|
| Celltrion Healthcare Japan KK | |
Cellemedy Co., Ltd.
Cellemedy Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Cellemedy Co., Ltd. develops next-generation cancer treatments to improve the health of people suffering from cancer. The company is based in Seongnam-si, South Korea. The South Korean company was founded in 2016. The CEO is Ha-Chul Kim. | Commercial Services |
Novalgen Ltd.
Novalgen Ltd. BiotechnologyHealth Technology Part of Convergys Capital Ltd., Novalgen Ltd. is a clinical stage immunology company based in Northwood Hills, UK. Novalgen is developing breakthrough immunotherapies for people with immunologically driven diseases using their autoregulation platform. The British company's lead program, NVG-111, is an ROR1-targeting bispecific antibody T-cell engager for the treatment of both hematological malignancies and solid tumors using their breakthrough bispecific antibody technology. The company's lead AR program, NVG-222, builds on the success of NVG-111 and is primed for entry into the clinic in 2024. The company was founded by Amit Chunilal Nathwani and has been the CEO since incorporation. | Health Technology |
| Novelgen Co. Ltd(South Korea) |
- Borsa valori
- Insiders
- Seung Suh Hong
- Esperienza
